logo

For the Inventor, By the Inventor

Valby, Denmark

Martin Juhl

USPTO Granted Patents = 19 

Average Co-Inventor Count = 4.1

ph-index = 8

Forward Citations = 142(Granted Patents)


Company Filing History:

goldMedal19 out of 506 
 
H. Lundbeck A/s
 patents

Years Active: 2020-2025

Loading Chart...
19 patents (USPTO):Explore Patents
1. 12479801 - Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4',5′:5,6]benzo[1,2-g]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline-6,7-diol (2025-11-25),
2. 12421271 - Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR, 10AR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid (2025-09-23),
3. 12398169 - Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid (2025-08-26),
4. 12391650 - Catecholamine prodrugs for use in the treatment of Parkinson's disease (2025-08-19),
5. 12384765 - Catecholamine prodrugs for use in the treatment of Parkinson's Disease (2025-08-12),
6. 12319710 - Catecholamine prodrugs for use in the treatment of Parkinson's diseases (2025-06-03),
7. 12226428 - Catecholamine prodrugs for use in the treatment of Parkinson's disease (2025-02-18),
8. 12152029 - Crystalline forms of a MAGL inhibitor (2024-11-26),
9. 11866410 - Process for the manufacturing of (6AR,10AR)-7-propyl-6,6A,7,8,9,10,10A,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4AR, 10AR)-1-propyl-1,2,3,4,4A,5,10,10A-octahydro-benzo[G]quinoline-6,7-diol (2024-01-09),
10. 11858954 - Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid (2024-01-02),
11. 11851456 - Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid (2023-12-26),
12. 11827665 - Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid (2023-11-28),
13. 11707476 - Catecholamine prodrugs for use in the treatment of parkinson's disease (2023-07-25),
14. 11168056 - Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4',5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol (2021-11-09),
15. 11130775 - Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid (2021-09-28),

Title: Inventor Spotlight: Martin Juhl, Pioneering Treatments for Neurodegenerative Diseases

Introduction:

Martin Juhl, a talented inventor based in Valby, Denmark, has made significant contributions to the field of pharmaceuticals with his innovative patents aimed at treating neurodegenerative diseases. With a total of 11 patents to his name, Juhl's work focuses on developing new processes and compounds for combating conditions like Parkinson's Disease.

Latest Patents:

Juhl's recent patents showcase his dedication to advancing treatment options for neurodegenerative diseases. His inventions include a novel process for manufacturing compounds essential for treating Parkinson's Disease, such as (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-g]quinoline. These compounds hold promise for patients suffering from such debilitating conditions.

Career Highlights:

Currently employed at H. Lundbeck A/S, a prominent pharmaceutical company, Martin Juhl continues to push the boundaries of pharmaceutical innovation. His expertise in drug development and patenting has garnered recognition within the industry, positioning him as a key player in the fight against neurodegenerative diseases.

Collaborations:

Juhl's innovative work is complemented by collaborations with esteemed colleagues such as Lisbet Kværnø and Mikkel Fog Jacobsen. Together, they form a dynamic team dedicated to driving forward new solutions for complex medical challenges, fostering a culture of innovation and excellence.

Conclusion:

In conclusion, Martin Juhl stands out as a visionary inventor whose passion for developing pioneering treatments for neurodegenerative diseases is truly commendable. His patents not only demonstrate his technical prowess but also signify a deep commitment to improving the lives of individuals affected by these conditions. Juhl's contributions to the field of pharmaceuticals are invaluable, opening up new possibilities for the future of healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…